Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)

Ken d’Entremont, Chief Executive Officer and Director, Medexus Inc.

Ken d’Entremont is the founder, president, and CEO of Medexus Inc. Previously, he was the general manager and vice president of business development at Sanofi, where he led the in-licensing initiatives for Sanofi Canada. Mr. d’Entremont holds a Bachelor of Science in Chemistry from McMaster University.

Marcel Konrad, Chief Financial Officer, Medexus Inc.

Marcel Konrad joined Medexus in 2021 from CareDx, Inc. (Nasdaq: CDNA), a precision medicine solutions company, where he served as Senior Vice President Finance & Accounting and Vice President, Corporate Controller. Mr. Konrad brings over 20 years of experience in Accounting, Finance and Business across various global markets that include Chief Financial Officer at Santen Inc, a US subsidiary of Santen Pharmaceuticals, a Japanese eye care company and various roles at Novartis both in the US and Switzerland. Mr. Konrad was an Auditor with KPMG. He holds an International MBA from the University of San Diego and has a Masters of Business Administration from HEC Lausanne, Switzerland. Mr. Konrad is an active US CPA.

Frank Candido, Managing Partner, Direct Financial Strategies and Communications Inc.

Frank Candido is currently the managing partner at Direct Financial Strategies and Communications Inc., a company that he founded in 2006 and which specializes in the consulting of private and publicly listed micro-cap and small cap companies as well as providing ongoing public and investor relations services. Mr. Candido has been retained by Medexus as an investor relations consultant since it went public in 2018. Mr. Candido is a graduate of Concordia University (Montreal, Canada) with a BA in Economics and McGill University (Montreal, Canada) with a Graduate Diploma in Finance.